Fate Therapeutics
FATE
S$1.43
Share price
0.00%
Change (1 day)
-66.57%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total debt
Total debt on the balance sheet as of March 2025 : S$0.10 Billion
According to Fate Therapeutics 's latest financial reports the company's total debt is S$0.10 Billion. A company’s total debt is the sum of all current and non-current debts.
Fate Therapeutics - Total debt on balance sheet (from 2012 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | S$0.11 B | -15.24% |
| 2023-12-31 | S$0.13 B | -6.71% |
| 2022-12-31 | S$0.14 B | -5.57% |
| 2021-12-31 | S$0.15 B | 20.59% |
| 2020-12-31 | S$0.12 B | 254.58% |
| 2019-12-31 | S$36.3 M | 78.53% |
| 2018-12-31 | S$20.33 M | 2.67% |
| 2017-12-31 | S$19.8 M | 28.04% |
| 2016-12-31 | S$15.46 M | -40.04% |
| 2015-12-31 | S$25.79 M | -0.43% |
| 2014-12-31 | S$25.9 M | 1080.67% |
| 2013-12-31 | S$2.19 M | -51.15% |
| 2012-12-31 | S$4.49 M | -28.32% |
| 2011-12-31 | S$6.26 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | S$1.71 B | 1,512.58% | 🇺🇸 USA |
 Becton Dickinson BDX | S$24.56 B | 23,025.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | S$0.49 B | 367.56% | 🇺🇸 USA |
 Avidity Biosciences RNA | S$7.61 M | -92.83% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | S$0.57 B | 437.03% | 🇺🇸 USA |